Contact

Biotech sector operations in June


,
Integral service around a transaction
BY : Diego GutiérrezJune Fri, 2015
So far in June, two Spanish biotech companies have completed financing rounds, Histocell and Biótica, which supports the conclusion reached by experts in the sector on cyt 60 minutes. "The 21st century will be the century of biotechnology with more than 500 companies created in the sector in the first decade".

 

 

bio junio

 

Histocell cierra una ronda de $2,5M

La biofarmacéutica vasca  Histocell, especialista en medicina regenerativa y terapia celular, ha cerrado una ronda de capital increase por importe de 2.5 M€ para el lanzamiento en el mercado internacional a finales de 2015  de su producto para cicatrización Reoxcare.

Esta es  la primera de las rondas de financiación que Histocell planea realizar en su plan estratégico 2015-2020, pero Las necesidades de inversión alcanzan los cuatro millones de euros, que serán destinados fundamentalmente a completar el desarrollo de tres productos sanitarios y finalizar las fases clínicas de dos medicamentos celulares.

 En la ronda han participado los principales accionistas de Histocell, entre ellos Orza AIE, vehículo inversor de Geroa and Elkarkidetza, Gestión de Capital Riesgo del País Vasco y el Grupo IMQ. Además también ha entrado como nuevo socio BI de Seed Capital Bizkaia.
For the time being, the company has already reached agreements for the marketing of Reoxcare in different European and Asian markets, such as the one signed with the company Luqa Pharma for China, Hong Kong and Macao.

Biótica cierra una ronda de financiación

La compañía de base tecnológica Biótica, ha cerrado una ronda a la que han acudido Caixa Capital Risc, mediante el fondo Caixa Capital Micro II, el fondo ComVal Emprende, gestionado por Clave Mayor y  anteriores accionistas como los socios promotores Adrián Fortuño, Guillermo Rodríguez y el Iproma (Grupo Gimeno).

Los fondos captados permitirán a Biótica impulsar el lanzamiento comercial de su sistema online de detección de legionella, Legiolab.

La tecnológica, localizada en el Parque Científico, Tecnológico y empresarial de la Universidad Jaume I de Castellón, se dedica al desarrollo y comercialización de sistemas para la detección rápida de microorganismos patógenos. Cuenta en la actualidad con varios productos en fase de comercialización, como es el caso del test LEGIPID y CLEANPID, ambos comercializados internacionalmente.

Escenario de la biotecnología en España

 Cristina Garmendia, presidenta de la Fundación Cotec para la innovación tecnológica y exministra de Ciencia e Innovación; Regina Revilla, presidenta de la Asociación Española de Bioempresas (Asebio), y Andrés Ballesteros, CEO y fundador de la compañía Vivia Biotech hablaron en el tercer debate de “CyT en 60 minutos“ sobre el pasado presente y futuro de la biotecnología.

Entre las principales conclusiones a las que llegaron destacamos que el siglo XXI es el siglo de la biotecnología en España con una primera década prodigiosa, se  han creado más de 500 empresasen los últimos 15 años, cifra que sitúa, como confirmó Revilla, a España “como uno de los países que más biotecnológicas ha creado este siglo”

Además  el capital riesgo internacional mira con muy buenos ojos el sector biotecnológico español, algo que no sucedía hace años. Los tres ponentes coincidieron en que hay que desarrollar más y mejor el entorno financiero para que el capital riesgo entre en España, se asiente, y pueda salir con facilidad cuando ya no sea necesaria su presencia en el desarrollo empresarial.

Si estas buscando financiación, tanto pública como privada , ponte en contacto con nosotros a través del +34. 946424142. Abra-Invest cuenta con un equipo con gran experiencia en ambos campos.

Other posts that may interest you

Biotech investment news: Era Biotech, Aura Bioscience, Quirumed and others (March 2015)

Operations Biotechnology February 2015

 

 

The M&A Professionals

Meet our services

CONTACT US

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
crossmenu